Danaher presents growth opportunities post-spinoff
The bull case for Danaher is that its transition away from a broad conglomerate has left a highly attractive growth story focused on life sciences instruments.
The argument
The guest argued that Danaher was previously a glamorous stock that fell off the radar due to corporate restructuring and spinoffs, but now offers compelling value at its current valuation.
The thesis, stress-tested
✓ What validates it
- ✓Stronger-than-expected demand and revenue growth in the life sciences instrument division
▸ Risks discussed
- ▸Market rotation away from healthcare and defensive growth back into high-beta technology
Hear it yourself
"But if you look at what's left in Danaher now, there's some really interesting growth stories there on the instrument side. So I think that there's places again where you had these glamorous stocks previously and they sort of fell off the radar screen, and I think that there's opportunity. Simple dhr in your vailue line."
00:00 / 00:20
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE